Sequent Scientific Ltd (VIYASH) Q1FY26 Concall Summary - Jun-2025 Qtr
Performance Overview
- Sequent Scientific demonstrated strong Q1 FY26 performance, with revenue reaching INR 4,414 million, a 13.1% YoY increase.
- Pre-ESOP EBITDA saw significant growth, reaching INR 602 million, with a margin of 13.6%.
- Formulation business, contributing 75% of total revenue, maintained a 13% YoY growth and 11% QoQ growth.
- API business achieved momentum, exceeding INR 1,000 million in revenue for the quarter, showing 14% YoY and 21% QoQ growth.
- The merger with Viyash Life Sciences is progressing as planned.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.